PATH vs RAPP
Uipath Inc (PATH) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
RAPP does not have a complete income-statement cache yet.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the PATH and RAPP stock pages for the full models.
Not investment advice.